375 related articles for article (PubMed ID: 14523280)
21. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
22. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
23. Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study.
Young J; De Geest S; Spirig R; Flepp M; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Telenti A; Vernazza P; Battegay M; Bucher HC;
BMJ; 2004 Jan; 328(7430):15. PubMed ID: 14703538
[TBL] [Abstract][Full Text] [Related]
24. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
25. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting.
Montaner JS; Lima VD; Harrigan PR; Lourenço L; Yip B; Nosyk B; Wood E; Kerr T; Shannon K; Moore D; Hogg RS; Barrios R; Gilbert M; Krajden M; Gustafson R; Daly P; Kendall P
PLoS One; 2014; 9(2):e87872. PubMed ID: 24533061
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
Sterling TR; Chaisson RE; Moore RD
AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
[TBL] [Abstract][Full Text] [Related]
27. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
[TBL] [Abstract][Full Text] [Related]
28. [Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy].
Reus S; Portilla J; Gimeno A; Sánchez-Payá J; García-Henarejos JA; Martínez-Madrid O; Usó J; Roca B; Galindo MJ; López-Aldeguer J
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):142-9. PubMed ID: 14987534
[TBL] [Abstract][Full Text] [Related]
29. [Sex specific mortality in HIV/AIDS patients receiving antiretroviral therapy and risk factors in Xinjiang Uygur autonomous region].
Ni M; Chen X; Ma Y; Hu X
Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Sep; 36(9):971-5. PubMed ID: 26814865
[TBL] [Abstract][Full Text] [Related]
30. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
31. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
Bogaards JA; Weverling GJ; Geskus RB; Miedema F; Lange JM; Bossuyt PM; Goudsmit J
Antivir Ther; 2003 Feb; 8(1):43-50. PubMed ID: 12713063
[TBL] [Abstract][Full Text] [Related]
32. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
Katsarou O; Touloumi G; Antoniou A; Kouramba A; Hatzakis A; Karafoulidou A
Haemophilia; 2005 Jul; 11(4):360-5. PubMed ID: 16011588
[TBL] [Abstract][Full Text] [Related]
33. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study.
Kouanda S; Meda IB; Nikiema L; Tiendrebeogo S; Doulougou B; Kaboré I; Sanou MJ; Greenwell F; Soudré R; Sondo B
AIDS Care; 2012; 24(4):478-90. PubMed ID: 22148973
[TBL] [Abstract][Full Text] [Related]
34. Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009.
Schwartz SR; Kumwenda N; Kumwenda J; Chen S; Mofenson LM; Taylor AW; Fowler MG; Taha TE
Matern Child Health J; 2016 Mar; 20(3):542-9. PubMed ID: 26525557
[TBL] [Abstract][Full Text] [Related]
35. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.
Hung CC; Chen MY; Hsiao CF; Hsieh SM; Sheng WH; Chang SC
AIDS; 2003 Dec; 17(18):2615-22. PubMed ID: 14685055
[TBL] [Abstract][Full Text] [Related]
36. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
[TBL] [Abstract][Full Text] [Related]
37. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
38. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).
Kim JH; Psevdos G; Gonzalez E; Singh S; Kilayko MC; Sharp V
Infection; 2013 Apr; 41(2):545-51. PubMed ID: 23264096
[TBL] [Abstract][Full Text] [Related]
39. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
40. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]